Published Studies Related to Pletal (Cilostazol)
Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. [2011.04]
OBJECTIVES: The aim of this study was to assess the degree of platelet inhibition by adjunctive cilostazol in patients with acute myocardial infarction (AMI) according to hepatic cytochrome P450 2C19 (CYP2C19) genotype. BACKGROUND: Although adjunctive cilostazol intensifies platelet inhibition in AMI patients, it is not established whether this regimen can be free from the effect of CYP2C19 loss-of-function variants (*2/*3)... CONCLUSIONS: Compared with high-MD clopidogrel, adjunctive cilostazol significantly enhances platelet inhibition and reduces the rate of HPR, especially in AMI patients with CYP2C19 loss-of-function variants. (Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism [ACCELAMI2C19]; NCT00915733). Copyright (c) 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial. [2011.04]
OBJECTIVE: To evaluate whether the addition of cilostazol to dual antiplatelet therapy (DAT, aspirin plus clopidogrel) can attenuate clopidogrel on-treatment platelet reactivity (OPR) in patients with the CYP2C19 loss-of-function (LOF) allele... CONCLUSION: TAT significantly reduced OPR compared with DAT in carriers of the CYP2C19 LOF allele, but not in non-carriers. These data suggest that the addition of cilostazol to DAT may be a good strategy to attenuate CYP2C19 LOF-related high OPR.
A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. [2011.03.15]
OBJECTIVES: The purpose of this study was to determine whether cilostazol reduces intimal hyperplasia in patients undergoing long zotarolimus-eluting stent implantation (stent length: >/= 30 mm) for native long coronary lesions (length: >/= 25 mm). BACKGROUND: Restenosis after drug-eluting stent implantation remains a significant clinical problem in long coronary lesions... CONCLUSIONS: Patients receiving triple antiplatelet therapy after long zotarolimus-eluting stent implantation had decreased extent of late luminal loss, percent intimal hyperplasia volume, and angiographic restenosis, resulting in a reduced risk of 12-month target lesion revascularization compared with patients receiving dual antiplatelet therapy. (Triple Versus Dual Antiplatelet Therapy after ABT578-Eluting Stent; NCT00589927). Copyright (c) 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. [2011.01.18]
OBJECTIVES: We aimed to test whether cilostazol has beneficial effects in the real-world patients treated with intracoronary drug-eluting stents (DES). BACKGROUND: The addition of cilostazol on the conventional dual antiplatelet therapy has been reported to reduce platelet reactivity and to improve clinical outcomes after percutaneous coronary intervention in previous studies... CONCLUSIONS: Despite the greater reduction of platelet reactivity by addition of cilostazol to conventional DAT, TAT did not show superiority in reducing the composite of adverse cardiovascular outcomes after DES implantation. (The Efficacy of CILostazol ON Ischemic Complications After DES Implantation [CILON-T]; NCT00776828). Copyright A(c) 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Study design and rationale of "Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial. [2011.01.12]
BACKGROUND: Probucol, a cholesterol-lowering agent that paradoxically also lowers high-density lipoprotein cholesterol has been shown to prevent progression of atherosclerosis. The antiplatelet agent cilostazol, which has diverse antiatherogenic properties, has also been shown to reduce restenosis in previous clinical trials...
Clinical Trials Related to Pletal (Cilostazol)
Fasting Study of Cilostazol Tablets 100 mg and PletalŪ Tablets 100 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan's cilostazol 100
mg tablets and Otsuka's PletalŪ 100 mg tablets following a single, oral 100 mg(1 x 100 mg)
dose administered under fasting conditions.
Evaluation of Cilostazol in Combination With L-Carnitine [Recruiting]
The purpose of this study is to see how safe and effective L carnitine taken with cilostazol
is compared to placebo taken with cilostazol for people with intermittent claudication. A
second purpose of the study is to see if L-carnitine is absorbed into the blood stream.
Cilostazol Augmentation Study in Dementia [Recruiting]
The purpose of this study is to examine the effects of cilostazol augmentation in mild to
moderate Alzheimer disease patients with subcortical white matter hyperintensities (WMHI)
treated by donepezil.
Dementia is the most disabling disease in the old age. The prevalence of dementia is 5-10%
of the elders. AchEIs (donepezil, galantamine, rivastigmine) are used to treat mild to
moderate dementia, but these drugs only relate to symptomatic improvement and the response
rates are less than 30%.
Cilostazol is a cyclic adenosine monophosphate phosphodiesterase 3 inhibitor (PDE3I) and
used as antiplatelet agent in subcortical vascular disease (WMHI). And it upregulates
phosphorylation of cyclic adenosine monophosphate-pathway response element binding protein
(CREB) which plays a crucial role in memory enhancement and synaptic plasticity related to
The investigators will try cilostazol augmentation in dementia patients with WMHI receiving
donepezil to see the addictive effects of cilostazol using cognitive tasks and PET imaging.
A Study on the Effect of Cilostazol in Patients With Chronic Tinnitus [Recruiting]
1. Overview of tinnitus Tinnitus is a noisy sound which is perceived without any external
sound source. According to the survey of the US, 10-20% of adult have the symptom of
tinnitus and 3-5% of tinnitus patients have severe discomfort of daily life. Severe
tinnitus can result in psychiatric problems such as depression and anxiety disorders.
Enhancement of environmental sound, hearing aids, sound generators, cognitive therapy,
transcranial magnetic therapy, and drug therapy have been tried for treatment of
tinnitus. Nitric oxide(NO) is a well-known neurotransmitter acting as a vasodilator
through regulation of production of cyclic guanosine monophosphate(cGMP) and can be
found in various sites of cochlea. It is reported that cGMP enhances activity of
protein kinase A (PKA), a mediator of platelet aggregation inhibition and
vasodilatation and results in increase of vascular flow.
2. Characteristics of the clinical research drug, cilostazol Cilostazol inhibits
phosphodiesterase type 3 (PDE3) selectively and increases amount of cAMP by inhibition
of degradation of cyclic adenosine monophosphate(cAMP). cAMP again by increasing the
active form of PKA suppress the production of blood clots and increase blood flow by
expanding blood vessels. Anti-platelet activity and vasodilatation effect of cilostazol
have been used for improvement of diabetic peripheral vascular disorders and
suppression of stroke recurrence. Previous studies reported that by increasing the
activity of NO and PKA, the blood flow of stria vascularis and cochlear hair cells can
be improved. These studies implies that cilostazol, which causes inhibition of PDE3 and
increase of PKA, can have a potential effect on improvement of tinnitus by increase of
blood flow to peripheral cochlear cells. Thus, we hypothesized that cilostazol, which
has been widely used for enhancing peripheral blood flow, can bring improvement of
tinnitus by causing better peripheral blood flow of cochlea.
3. The aim of the study We planned this study to validate the assumptions of the
background. The aim of our study is whether administration of cilostazol can improve
tinnitus in terms of subjective degree of symptoms in chronic tinnitus patients.
Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety [Recruiting]
Based upon evidence of efficacy and safety of both cilostazol and probucol administration in
independent randomized controlled trials in PAD and CAD, the present trial seeks to
investigate the effect of concomitant administration of cilostazol and probucol on FMD
compared to each drug individually, as well as to evaluate biomarker measures and safety
indices in this context.
Reports of Suspected Pletal (Cilostazol) Side Effects
Interstitial Lung Disease (12),
Cerebral Infarction (11),
Condition Aggravated (8),
Cerebral Haemorrhage (7),
Renal Failure Acute (7),
Hepatic Function Abnormal (6), more >>